Gallium-68 NY 118 - Norroy Bioscience
Alternative Names: 68Ga-NY-118; Gallium-68 NY-118Latest Information Update: 27 Aug 2024
At a glance
- Originator Norroy Bioscience
- Class Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Gastrointestinal cancer
Most Recent Events
- 31 Jul 2024 Preclinical trials in Gastrointestinal cancer (Diagnosis) in China (Parenteral) (Norroy Bioscience pipeline; July 2024)
- 31 Jul 2024 Norroy Bioscience intends to file a regulatory application for approval of gallium-68 NY 118 for Gastrointestinal cancer (Diagnosis) in the second half of 2026 (Norroy Bioscience pipeline, July 2024)
- 31 Jul 2024 Norroy Bioscience plans IND-enabling studies for Gastrointestinal cancer (Diagnosis) in the first half of 2025 (Norroy Bioscience pipeline, July 2024)